跳至主要内容
临床试验/NL-OMON40458
NL-OMON40458撤回3 期

*Efficacy and safety of intratympanic dexamethasone compared to intratympanic gentamicin in patients with proven unilateral Ménière*s disease*; a randomised, double-blind, controlled non-inferiority trial
 - DEXAvsGENTA trial

Gelre Ziekenhuizen0 个研究点目标入组 66 人开始时间: 待定最近更新:
适应症

试验速览

阶段
3 期
状态
撤回
入组人数
66

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • *Definite unilateral Ménière's disease according to AAO-HNS criteria: two or more definitive spontaneous episodes of vertigo for at least 20 minutes, AND audiometric confirmation of a sensorineural hearing loss, AND tinnitus (other causes excluded)
  • *Not responding to oral medical treatment for at least six months.
  • *Age above 18 years at the start of the trial.
  • *Willing to adhere to the follow up assessments.

排除标准

  • *Ménière's disease in advanced stages (not having vertigo attacks).
  • *bilateral Ménière's disease.
  • *Severe disability (e.g. neurological, orthopaedic, cardiovascular) or serious concurrent illness that might interfere with treatment or follow up.
  • *Active additional neuro-otologic disorders that may mimic Ménière's disease (e.g. vestibular migraine, vertebro-basilar TIAs, acoustic neuroma).
  • *Concurrent ear pathology that may interfere with IT injections (e.g. active middle ear disease).
  • *Family history of unexplained deafness (possibility of genetic susceptibility to gentamicin toxicity).
  • *History of known adverse and/or allergic reaction to steroids or gentamicin.
  • *Women of child bearing age not using contraception, pregnant women or nursing women.

研究者

相似试验